Phagenesis Ltd Secures $42 Million in Funding for Groundbreaking Dysphagia Treatment Innovation

We are thrilled to announce that Phagenesis Ltd has successfully raised £42 million in funding to further our mission of revolutionizing the treatment of dysphagia. This substantial investment enables us to accelerate the development and commercialization of our flagship product, the Phagenyx, a groundbreaking device that employs Pharyngeal Electrical Stimulation (PES) to restore swallowing function in those affected by this debilitating condition. With dysphagia impacting millions globally, our innovative, non-invasive approach aims to not only enhance patients’ quality of life but also empower them to enjoy their meals without fear or discomfort. The funds will be allocated towards expanding clinical trials, enhancing manufacturing capabilities, and increasing our outreach to healthcare providers worldwide, ensuring more individuals can access this life-changing technology. Our commitment to evidence-based practices and collaboration with the medical community has already shown promising results in improving swallowing abilities among patients. As we continue on this journey, we invite you to join us in transforming dysphagia care. Stay connected with us on LinkedIn to follow our latest developments, clinical achievements, and the inspiring stories of those we aim to help. Together, we are dedicated to changing lives and redefining the standard of care for dysphagia patients everywhere. Thank you for your ongoing support as we turn our vision into reality!